Back To TopGet Opthea Updates

Shaping the Future of Wet AMD and Retinal Diseases

Our Vision

Advancing bold therapeutic innovation and inspiring transformation in the global retinal community.

Our Mission

Dedicated to improving and protecting vision in people with retinal diseases.

Company Overview

Opthea Limited (NASDAQ: OPT, ASX: OPT) is a global biopharmaceutical company aspiring to become the leader of therapeutic innovation in retinal diseases.

We started with a vision of the future, where the impact of retinal disease is reduced, and patients’ quality-of-life is enhanced. With people as our focus, we assembled a world-class team of ophthalmology experts in pursuit of breakthrough therapies. Together we focused on scientific innovation for those who suffer from retinal disease. Today, we are translating our discoveries into promising new medicines.

Company Overview Scientists

History

 

Circadian Technologies listed on the Australian Securities Exchange in 1985.

1985
2008

Circadian focused its strategy to concentrate on the development of biologics-based therapies.

The company was renamed Opthea Limited and began developing OPT-302 for retinal eye diseases.

Initiated Phase 1/2A Clinical Trial in wet AMD.

2015
2019

Opthea announces positive data from a Phase 2B trial of OPT-302 in patients with wet AMD.

Opthea began trading on the Nasdaq under the ticker symbol “OPT.”

Announced results of Phase 2 Clinical Trial in Diabetic Macular Edema.

2020
2021

Initiated Phase 3 Shore and Coast Clinical Trials in wet AMD.

Opthea announced a non-dilutive financing transaction for up to US $170 million from Launch Therapeutics.

2022
2023

Continuing to enroll patients into our global Phase 3 clinical trial program

Management Team

Our executive leadership team has the experience, determination, and resources to make a positive and significant impact on the retinal community. We are building a culture of success that drives our transformation and leadership role as an important global ally in retinal care. Click the links below to learn more about the people who are leading our patient-focused mission.

Fred Guerard • PharmD, MS
Chief Executive Officer

Peter Lang • MBA
Chief Financial Officer

Megan Baldwin • PhD, MAICD
Founder, Chief Innovation Officer and Executive Director

Judith Robertson • MBA
Chief Commercial Officer

Julie Clark • MD
Senior Vice President of Clinical Development

Fang Li • PhD
Senior Vice President Regulatory Affairs

Bruno Gagnon • BPharm, MSc
Senior Vice President, Global Clinical Operations

Karen Adams • B.BBUS, CPA, GAICD, FCC GFIA
Vice President Finance and Company Secretary

Mark O’Neill
Vice President CMC

Mike Gerometta • PhD
Head of CMC Development

Sarika Gulhar  • PhD
Executive Director of Human Resources

Ian Leitch • PhD
Director of Clinical Research

Board of Directors

Our board believes in the promising future of our company and in the power of our transformational science and technology to establish a new standard-of-care for retinal diseases. Our board members bring the strategic expertise and necessary skills needed to help the company succeed, and collectively they provide important oversight and governance of the business.

Jeremy Levin

Jeremy Levin
Chairman of the Board

Megan Baldwin
Founder, Chief Innovation Officer and Executive Director

Lawrence Gozlan

Lawrence Gozlan
Non-Executive Director

Julia Haller

Julia Haller
Non-Executive Director

Susan Orr

Susan Orr
Non-Executive Director

Quinton Oswald

Quinton Oswald
Non-Executive Director

Daniel Spiegelman

Daniel Spiegelman
Non-Executive Director

Anshul Thakral
Non-Executive Director

Board of Directors Committee Composition

Board of Directors Composition

Board of Directors Committee Composition

Jeremy Levin

Jeremy Levin

Daniel Spiegelman

Dan Spiegelman

  • Audit & Risk Committee Chair
  • Nomination Committee Member

Julia Haller

Julia Haller

  • Remuneration Committee Member
  • Clinical Committee Member

Lawrence Gozlan

Lawrence Gozlan

  • Nomination Committee Chair
  • Remuneration Committee Member

Susan Orr

Susan Orr

  • Clinical Committee Chair
  • Audit & Risk Committee Member

Quinton Oswald

Quinton Oswald

  • Remuneration Committee Chair
  • Clinical Committee Member
  • Nomination Committee Member
  • Audit & Risk Committee Member

Anshul Thakral

Anshul Thakral

  • Clinical Committee Member

Clinical Advisory Board

Opthea engages with Clinical Advisors who are aligned with our patient-centric mission to obtain independent expert advice.

Tim Jackson

Tim Jackson
PhD, MB, ChB, FRCOphth • National Health Service Consultant Ophthalmic Surgeon at King’s College Hospital, London

Jason Slakter

Jason Slakter
MD • Clinical Professor of Ophthalmology at New York University School of Medicine, and partner at Vitreous Retina Macula Consultants Of New York

Charles C. Wykoff
MD, PhD • Director of Research, Retina Consultants of Texas; Chairman of Research and Clinical Trials Committee, Retina Consultants of America; Deputy Chair for Opthalmology, Blanton Eye Institute, Houston Methodist Hospital

Medical Advisors

Opthea engages with Medical Advisors who are aligned with our patient-centric mission to obtain independent expert advice to support sozinibercept development and launch preparation.

Arshad M. Khanani • MD, MA, FASRS
Chief Medical Advisor
Managing Partner, Director of Clinical Research and Director of Fellowship at Sierra Eye Associates, and Clinical Associate Professor at the University of Nevada, Reno School of Medicine.

Connect with Us

We appreciate your interest in Opthea.

Get Opthea Updates

Company news, pipeline updates, and more